Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 10.02% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.6 billion (up 17.31% YoY), and the FY2025 full-year result was $1.4 billion, up 12.14% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.4 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2025 to a low of $739.1 million in Q3 2022.
• A 5-year average of $1.0 billion and a median of $914.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 60.58% in 2022, while the deepest fall reached 1.49% in 2022.
• Tracing ANIP's Liabilities and Shareholders Equity over 5 years: stood at $760.1 million in 2022, then rose by 18.99% to $904.4 million in 2023, then surged by 42.02% to $1.3 billion in 2024, then gained by 12.14% to $1.4 billion in 2025, then retreated by 1.28% to $1.4 billion in 2026.
• Business Quant data shows ANIP's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.